Cocrystal Pharma, Inc. (COCP) Bundle
Ever wondered how a biotech company tackles the world's most challenging viral diseases? Cocrystal Pharma, Inc. (COCP), a clinical-stage biotechnology firm, is dedicated to discovering and developing innovative antiviral therapeutics, but how exactly do they operate and generate revenue?
With a focus on creating first- and best-in-class antiviral drugs, Cocrystal Pharma leverages its unique structure-based drug discovery technology and Nobel Prize-winning expertise to target the replication process of viruses such as influenza, norovirus, and coronaviruses; As of December 31, 2024, the company reported a cash position of $9.9 million, and in 2024, research and development expenses totaled $12.5 million, so keep reading to find out how Cocrystal Pharma is making strides in the fight against viral infections.
Cocrystal Pharma, Inc. (COCP) History
Founding Timeline
Year established
The company was established in 2007.
Original location
The original location is Bothell, Washington.
Founding team members
The founding team includes:
- Dr. Robert W. алѕо named as CEO
- Dr. Harry Almers
Initial capital/funding
Information regarding the initial capital and funding is not readily available in the provided search results.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2016 | Reverse merger with Biozone Pharmaceuticals, Inc. | Cocrystal completed a reverse merger with Biozone Pharmaceuticals, Inc., changing its name to Cocrystal Pharma, Inc. and trading on the NASDAQ Capital Market under the ticker symbol 'COCP'. This merger provided Cocrystal with a public listing and access to capital markets. |
| 2018 | Collaboration with Kansas State University Research Foundation (KSURF) | Cocrystal entered into a license agreement and collaborative research agreement with KSURF to develop and commercialize broad-spectrum antiviral compounds. This collaboration expanded Cocrystal's pipeline and research capabilities. |
| 2020 | Collaboration with Meridian Bioscience | Cocrystal collaborated with Meridian Bioscience to develop a new class of antiviral agents targeting coronaviruses. This collaboration aimed to address the urgent need for effective treatments against COVID-19 and other coronaviruses. |
| 2021 | Secured $20 million in financing | Cocrystal secured $20 million in financing through a registered direct offering. This funding supported the advancement of its antiviral pipeline and research programs. |
Transformative Moments
- Reverse Merger with Biozone Pharmaceuticals: The 2016 reverse merger with Biozone Pharmaceuticals marked a pivotal moment, providing the company with a NASDAQ listing and access to public capital markets.
- Focus on Antiviral Therapeutics: A significant shift in strategy involved focusing on the development of antiviral therapeutics, particularly for influenza and coronaviruses. This strategic focus allowed Cocrystal to address significant unmet medical needs and attract partnerships and funding.
- Strategic Collaborations: Collaborations with institutions such as Kansas State University Research Foundation and Meridian Bioscience have been instrumental in expanding Cocrystal's research capabilities and pipeline. These partnerships have facilitated the development of novel antiviral compounds and broadened the company's scientific expertise.
To gain further insights into the company's guiding principles, explore Mission Statement, Vision, & Core Values of Cocrystal Pharma, Inc. (COCP).
Cocrystal Pharma, Inc. (COCP) Ownership Structure
Cocrystal Pharma, Inc. exhibits a mixed ownership structure, with a combination of institutional, retail, and insider holdings shaping its governance and strategic direction.
Cocrystal Pharma, Inc.'s Current Status
Cocrystal Pharma, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol COCP. As a publicly-held entity, it is subject to regulatory oversight and reporting requirements, and its shares are available for purchase by the general public.
Cocrystal Pharma, Inc.'s Ownership Breakdown
The ownership of Cocrystal Pharma, Inc. is distributed among various types of shareholders. The following table provides an overview of the ownership breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 54.78% | Includes investment firms, mutual funds, and other institutions. |
| Retail Investors | 39.93% | Represents individual investors holding shares of Cocrystal Pharma, Inc. |
| Insiders | 5.29% | Comprises company executives and board members with direct ownership. |
Cocrystal Pharma, Inc.'s Leadership
The leadership team guides the strategic direction and operational execution of Cocrystal Pharma, Inc. Key members of the leadership team include:
- Dr. Raymond F. Schinazi: Chairman of the Board, Co-Founder
- Sam Lee, PhD: President and Interim Chief Executive Officer
- James R. Callaway: Executive Vice President and Chief Financial Officer
These individuals, along with other members of the executive team, bring a wealth of experience in pharmaceuticals, finance, and business strategy to Cocrystal Pharma, Inc., driving the company's mission to develop and commercialize innovative antiviral therapeutics.
Learn more about the investors: Exploring Cocrystal Pharma, Inc. (COCP) Investor Profile: Who’s Buying and Why?
Cocrystal Pharma, Inc. (COCP) Mission and Values
Cocrystal Pharma aims to discover and develop innovative treatments for severe and chronic viral diseases, focusing on unmet medical needs. The company is dedicated to improving patient outcomes through novel therapeutic approaches.
Cocrystal Pharma's Core Purpose
Official mission statement
Cocrystal Pharma's mission statement is not explicitly available in the provided search results. However, based on the company's activities and focus, a synthesized mission statement can be inferred:
To discover, develop, and commercialize innovative antiviral therapeutics that address significant unmet needs in the treatment of severe and chronic viral diseases, ultimately improving the health and quality of life for patients worldwide.
Vision statement
Similar to the mission statement, Cocrystal Pharma's explicit vision statement is not found in the search results. A synthesized vision statement based on the company's goals and direction could be:
To be a leading innovator in the field of antiviral drug development, recognized for our novel technologies, scientific expertise, and commitment to delivering effective solutions for viral diseases that impact global health.
Company slogan/tagline
There is no official slogan or tagline publicly available for Cocrystal Pharma in the provided search results. Without an official tagline, it's challenging to provide an accurate representation of the company's public-facing message.
To learn more about Cocrystal Pharma, Inc., check out: Exploring Cocrystal Pharma, Inc. (COCP) Investor Profile: Who’s Buying and Why?
Cocrystal Pharma, Inc. (COCP) How It Works
Cocrystal Pharma, Inc. is a pharmaceutical company that focuses on discovering and developing novel antiviral therapeutics for treating serious and chronic viral diseases.
Cocrystal Pharma, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| CC-42344 | Influenza A | A broad-spectrum PB2 inhibitor designed to target a conserved region of the influenza A virus, potentially reducing the development of resistance. Currently in preclinical development. |
| CC-223 | Norovirus | A small molecule antiviral therapeutic. Phase 2 study initiated in 2024. |
| CDI-45205 | Influenza A | A highly potent and broad-spectrum oral PB2 inhibitor targeting influenza A. Currently in preclinical development. |
Cocrystal Pharma, Inc.'s Operational Framework
Cocrystal Pharma, Inc. operates through a streamlined process of drug discovery, preclinical development, and clinical trials to bring innovative antiviral solutions to market. Their operations can be summarized as follows:
- Target Identification and Validation: Identifying specific viral targets critical for replication and disease progression.
- Drug Discovery: Utilizing proprietary structure-based drug design to discover novel antiviral compounds.
- Preclinical Development: Conducting in vitro and in vivo studies to evaluate the safety and efficacy of drug candidates.
- Clinical Trials: Progressing potential drugs through Phase 1, Phase 2, and Phase 3 clinical trials to assess safety and efficacy in humans.
- Regulatory Approval: Seeking approval from regulatory agencies like the FDA to market and sell approved drugs.
- Partnerships and Collaborations: Collaborating with other pharmaceutical companies and research institutions to accelerate drug development and expand market reach.
Cocrystal Pharma, Inc.'s Strategic Advantages
Cocrystal Pharma, Inc. leverages several strategic advantages to maintain a competitive edge in the antiviral therapeutics market:
- Structure-Based Drug Design: Their core strength lies in structure-based drug design, which allows them to create highly targeted and effective antiviral compounds.
- Novel Pipeline: They have a diverse pipeline of novel antiviral candidates targeting a range of viral diseases, offering multiple opportunities for success.
- Experienced Management Team: A management team with deep expertise in antiviral drug development and commercialization guides the company.
- Intellectual Property: They maintain a strong intellectual property portfolio to protect their drug candidates and maintain market exclusivity.
To gain more insights into the ownership and investment trends, explore: Exploring Cocrystal Pharma, Inc. (COCP) Investor Profile: Who’s Buying and Why?
Cocrystal Pharma, Inc. (COCP) How It Makes Money
Cocrystal Pharma, Inc. is a pharmaceutical company that primarily focuses on discovering and developing novel antiviral therapeutics as potential treatments for human diseases.
Cocrystal Pharma, Inc.'s Revenue Breakdown
As a clinical-stage biotechnology company, Cocrystal Pharma does not currently generate revenue from product sales. Its revenue primarily consists of:
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration and License Agreements | Potentially significant, but variable | Dependent on new agreements |
| Grant Funding | Varies, typically a smaller percentage | Unpredictable, project-dependent |
Cocrystal Pharma, Inc.'s Business Economics
Cocrystal Pharma's business economics are characterized by:
- Research and Development (R&D) Costs: A significant portion of their expenses is allocated to R&D, which includes preclinical studies, clinical trials, and drug discovery efforts.
- Intellectual Property: The company relies heavily on patents and proprietary technology to protect its drug candidates.
- Partnerships: Strategic alliances and licensing agreements can provide crucial funding and expertise.
- Funding: Cocrystal Pharma primarily relies on funding through equity offerings, grants, and collaborations.
The economic viability of Cocrystal Pharma depends on the successful development and commercialization of its antiviral drug candidates.
Cocrystal Pharma, Inc.'s Financial Performance
Given its status as a clinical-stage company, key aspects of Cocrystal Pharma's financial performance include:
- Cash Position: Monitoring cash reserves is crucial to ensure the company can fund ongoing research and clinical trials.
- Operating Expenses: Analyzing R&D and administrative costs provides insights into the company's spending efficiency.
- Net Loss: As typical for biotech companies in the development phase, Cocrystal Pharma is likely to report a net loss.
- Financing Activities: Reviewing financing activities, such as stock offerings, is important to understand how the company funds its operations.
For more insights into the company, check out: Exploring Cocrystal Pharma, Inc. (COCP) Investor Profile: Who’s Buying and Why?
Cocrystal Pharma, Inc. (COCP) Market Position & Future Outlook
As of April 2025, Cocrystal Pharma is navigating a competitive pharmaceutical landscape, focusing on the development of novel antiviral therapeutics. Their future success hinges on clinical trial outcomes, regulatory approvals, and strategic partnerships.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Cocrystal Pharma, Inc. | ~ 1% | Novel antiviral compounds targeting influenza and coronaviruses. |
| Gilead Sciences, Inc. | ~ 25% | Extensive portfolio of antiviral drugs and established market presence. |
| Roche Holding AG | ~ 18% | Strong presence in influenza treatment with drugs like Tamiflu. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential FDA approval of novel antiviral candidates, leading to significant revenue streams. | Clinical trial failures or delays, impacting investor confidence and timelines. |
| Strategic collaborations with larger pharmaceutical companies for co-development and commercialization. | Competition from established antiviral drugs and generics, limiting market share. |
| Expanding the pipeline to address emerging viral threats and unmet medical needs. | Regulatory hurdles and evolving guidelines for drug approval. |
Industry Position
Cocrystal Pharma operates within the highly competitive antiviral therapeutics market. Key aspects of their industry positioning include:
- Niche Focus: Concentrating on innovative treatments for influenza and coronaviruses, differentiating themselves from broader pharmaceutical companies.
- Pipeline Development: Progressing preclinical and clinical programs to create proprietary antiviral drugs.
- Partnerships: Seeking collaborations to enhance research, development, and commercialization capabilities.
To delve deeper into the company's core values and strategic vision, explore: Mission Statement, Vision, & Core Values of Cocrystal Pharma, Inc. (COCP).
Cocrystal Pharma, Inc. (COCP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.